Oleclumab
- Generic Name
- Oleclumab
- Drug Type
- Biotech
- CAS Number
- 1803176-05-7
- Unique Ingredient Identifier
- 5CRY01URYQ
- Background
Oleclumab is under investigation in clinical trial NCT03819465 (A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC).
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)
Phase 2
Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT06606847
- Locations
- 🇷🇺
Research Site, Ufa, Russian Federation
Durvalumab and Oleclumab in Resectable PDAC
Phase 2
Recruiting
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 22
- Registration Number
- NCT06060405
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 999
- Registration Number
- NCT05221840
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: Pemetrexed/CisplatinDrug: Pemetrexed/CarboplatinDrug: Carboplatin/Paclitaxel
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 630
- Registration Number
- NCT05061550
- Locations
- 🇹🇷
Research Site, Izmir, Turkey
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
Phase 2
Active, not recruiting
- Conditions
- Resectable Pancreatic AdenocarcinomaStage IB Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8Stage IIB Pancreatic Cancer AJCC v8Borderline Resectable Pancreatic AdenocarcinomaStage IA Pancreatic Cancer AJCC v8
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT04940286
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
Phase 2
Active, not recruiting
- Conditions
- Metastatic AngiosarcomaRefractory Dedifferentiated LiposarcomaMetastatic Dedifferentiated LiposarcomaRefractory OsteosarcomaRecurrent OsteosarcomaMetastatic OsteosarcomaRecurrent AngiosarcomaRecurrent Dedifferentiated Liposarcoma
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT04668300
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate CancerMetastatic Castration-Resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 59
- Registration Number
- NCT04089553
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
Phase 1
Terminated
- Conditions
- Metastatic Microsatellite-stable Colorectal Cancer
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 61
- Registration Number
- NCT04068610
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
Phase 2
Active, not recruiting
- Conditions
- Luminal B
- Interventions
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 147
- Registration Number
- NCT03875573
- Locations
- 🇧🇪
Universitaire Ziekenhuizen, Leuven, Belgium
🇧🇪Institut Jules Bordet, Bruxelles, Belgium
🇧🇪Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance
Phase 2
Active, not recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-02-07
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Target Recruit Count
- 114
- Registration Number
- NCT03833440
- Locations
- 🇫🇷
Assistance Publique Hopitaux de Marseille, Marseille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath